{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:39:03Z","timestamp":1773797943349,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00415-026-13647-x","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T12:26:38Z","timestamp":1770035198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Substrates of 8.5-year clinical outcomes in aquaporin-4 IgG-positive neuromyelitis optica spectrum disorders"],"prefix":"10.1007","volume":"273","author":[{"given":"Monica","family":"Margoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mor","family":"Gueye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Meani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Pagani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Valsasina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loredana","family":"Storelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Preziosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Moiola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Assunta","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-0479","authenticated-orcid":false,"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"issue":"2","key":"13647_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177\u2013189. https:\/\/doi.org\/10.1212\/WNL.0000000000001729","journal-title":"Neurology"},{"issue":"7","key":"13647_CR2","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1007\/s00415-024-12426-w","volume":"271","author":"P Preziosa","year":"2024","unstructured":"Preziosa P et al (2024) Moving towards a new era for the treatment of neuromyelitis optica spectrum disorders. J Neurol 271(7):3879\u20133896. https:\/\/doi.org\/10.1007\/s00415-024-12426-w","journal-title":"J Neurol"},{"key":"13647_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-334090","author":"P Siriratnam","year":"2024","unstructured":"Siriratnam P et al (2024) Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: a multicentre study. J Neurol Neurosurg Psychiatry. https:\/\/doi.org\/10.1136\/jnnp-2024-334090","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"13647_CR4","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/brain\/awz054","volume":"142","author":"J Palace","year":"2019","unstructured":"Palace J et al (2019) Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain 142(5):1310\u20131323. https:\/\/doi.org\/10.1093\/brain\/awz054","journal-title":"Brain"},{"key":"13647_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101868","volume":"38","author":"A Kunchok","year":"2020","unstructured":"Kunchok A et al (2020) Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 38:101868. https:\/\/doi.org\/10.1016\/j.msard.2019.101868","journal-title":"Mult Scler Relat Disord"},{"key":"13647_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.msard.2018.12.011","volume":"28","author":"MA Mealy","year":"2019","unstructured":"Mealy MA et al (2019) Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis\/preventive treatment, MRI lesion length and presence of symptomatic brain lesions. Mult Scler Relat Disord 28:64\u201368. https:\/\/doi.org\/10.1016\/j.msard.2018.12.011","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"13647_CR7","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1093\/brain\/aws109","volume":"135","author":"J Kitley","year":"2012","unstructured":"Kitley J et al (2012) Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 135(6):1834\u20131849. https:\/\/doi.org\/10.1093\/brain\/aws109","journal-title":"Brain"},{"issue":"22","key":"13647_CR8","doi-asserted-by":"publisher","first-page":"e2089","DOI":"10.1212\/WNL.0000000000006574","volume":"91","author":"SH Kim","year":"2018","unstructured":"Kim SH et al (2018) Racial differences in neuromyelitis optica spectrum disorder. Neurology 91(22):e2089\u2013e2099. https:\/\/doi.org\/10.1212\/WNL.0000000000006574","journal-title":"Neurology"},{"key":"13647_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.873576","volume":"13","author":"L Wang","year":"2022","unstructured":"Wang L et al (2022) Neuromyelitis optica spectrum disorder with anti-aquaporin-4 antibody: outcome prediction models. Front Immunol 13:873576. https:\/\/doi.org\/10.3389\/fimmu.2022.873576","journal-title":"Front Immunol"},{"issue":"4","key":"13647_CR10","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/brain\/awab394","volume":"145","author":"Y Guo","year":"2022","unstructured":"Guo Y et al (2022) Spectrum of sublytic astrocytopathy in neuromyelitis optica. Brain 145(4):1379\u20131390. https:\/\/doi.org\/10.1093\/brain\/awab394","journal-title":"Brain"},{"issue":"2","key":"13647_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/13524585211018987","volume":"28","author":"S Messina","year":"2022","unstructured":"Messina S et al (2022) Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis. Mult Scler 28(2):217\u2013227. https:\/\/doi.org\/10.1177\/13524585211018987","journal-title":"Mult Scler"},{"issue":"7","key":"13647_CR12","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1111\/ene.13321","volume":"24","author":"SH Kim","year":"2017","unstructured":"Kim SH et al (2017) Diffusion tensor imaging of normal-appearing white matter in patients with neuromyelitis optica spectrum disorder and multiple sclerosis. Eur J Neurol 24(7):966\u2013973. https:\/\/doi.org\/10.1111\/ene.13321","journal-title":"Eur J Neurol"},{"issue":"3","key":"13647_CR13","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1212\/01.wnl.0000106946.08741.41","volume":"62","author":"MA Rocca","year":"2004","unstructured":"Rocca MA et al (2004) Magnetization transfer and diffusion tensor MRI show gray matter damage in neuromyelitis optica. Neurology 62(3):476\u2013478. https:\/\/doi.org\/10.1212\/01.wnl.0000106946.08741.41","journal-title":"Neurology"},{"issue":"2","key":"13647_CR14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/ana.26419","volume":"92","author":"L Cacciaguerra","year":"2022","unstructured":"Cacciaguerra L et al (2022) Magnetic resonance imaging evaluation of perivascular space abnormalities in neuromyelitis optica. Ann Neurol 92(2):173\u2013183. https:\/\/doi.org\/10.1002\/ana.26419","journal-title":"Ann Neurol"},{"key":"13647_CR15","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001147","author":"J Muller","year":"2022","unstructured":"Muller J et al (2022) Choroid plexus volume in multiple sclerosis vs neuromyelitis optica spectrum disorder: a retrospective, cross-sectional analysis. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000001147","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"Pt 5","key":"13647_CR16","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/brain\/awl371","volume":"130","author":"SF Roemer","year":"2007","unstructured":"Roemer SF et al (2007) Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 130(Pt 5):1194\u20131205. https:\/\/doi.org\/10.1093\/brain\/awl371","journal-title":"Brain"},{"issue":"7","key":"13647_CR17","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1177\/1352458518778008","volume":"25","author":"MA Rocca","year":"2019","unstructured":"Rocca MA et al (2019) Cross-modal plasticity among sensory networks in neuromyelitis optica spectrum disorders. Mult Scler 25(7):968\u2013979. https:\/\/doi.org\/10.1177\/1352458518778008","journal-title":"Mult Scler"},{"issue":"11","key":"13647_CR18","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","volume":"80","author":"J Muller","year":"2023","unstructured":"Muller J et al (2023) Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review. JAMA Neurol 80(11):1232\u20131245. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3331","journal-title":"JAMA Neurol"},{"key":"13647_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.neuroimage.2017.04.034","volume":"155","author":"S Valverde","year":"2017","unstructured":"Valverde S et al (2017) Improving automated multiple sclerosis lesion segmentation with a cascaded 3D convolutional neural network approach. Neuroimage 155:159\u2013168. https:\/\/doi.org\/10.1016\/j.neuroimage.2017.04.034","journal-title":"Neuroimage"},{"issue":"3","key":"13647_CR20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.nic.2024.03.001","volume":"34","author":"M Filippi","year":"2024","unstructured":"Filippi M, Preziosa P, Margoni M, Rocca MA (2024) Diagnostic criteria for multiple sclerosis, neuromyelitis optica spectrum disorders, and myelin oligodendrocyte glycoprotein-immunoglobulin G-associated disease. Neuroimaging Clin N Am 34(3):293\u2013316. https:\/\/doi.org\/10.1016\/j.nic.2024.03.001","journal-title":"Neuroimaging Clin N Am"},{"key":"13647_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2024.109164","volume":"182","author":"V Visani","year":"2024","unstructured":"Visani V et al (2024) ASCHOPLEX: a generalizable approach for the automatic segmentation of choroid plexus. Comput Biol Med 182:109164. https:\/\/doi.org\/10.1016\/j.compbiomed.2024.109164","journal-title":"Comput Biol Med"},{"issue":"2","key":"13647_CR22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41380-023-02332-4","volume":"29","author":"M Gueye","year":"2024","unstructured":"Gueye M et al (2024) Choroid plexus and perivascular space enlargement in neuropsychiatric systemic lupus erythematosus. Mol Psychiatry 29(2):359\u2013368. https:\/\/doi.org\/10.1038\/s41380-023-02332-4","journal-title":"Mol Psychiatry"},{"issue":"3","key":"13647_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/hbm.1048","volume":"14","author":"VD Calhoun","year":"2001","unstructured":"Calhoun VD, Adali T, Pearlson GD, Pekar JJ (2001) A method for making group inferences from functional MRI data using independent component analysis. Hum Brain Mapp 14(3):140\u201351. https:\/\/doi.org\/10.1002\/hbm.1048","journal-title":"Hum Brain Mapp"},{"issue":"10206","key":"13647_CR24","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree BAC et al (2019) Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet 394(10206):1352\u20131363. https:\/\/doi.org\/10.1016\/S0140-6736(19)31817-3","journal-title":"Lancet"},{"issue":"5","key":"13647_CR25","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200450","volume":"12","author":"JL Bennett","year":"2025","unstructured":"Bennett JL et al (2025) Long-term efficacy and safety of satralizumab in patients with neuromyelitis optica spectrum disorder from the SAkuraMoon open-label extension study. Neurol Neuroimmunol Neuroinflamm 12(5):e200450. https:\/\/doi.org\/10.1212\/NXI.0000000000200450","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13647_CR26","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200071","author":"I Kleiter","year":"2023","unstructured":"Kleiter I et al (2023) Long-term efficacy of satralizumab in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder from SAkuraSky and SAkuraStar. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000200071","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"13647_CR27","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1177\/13524585211038291","volume":"28","author":"SJ Pittock","year":"2022","unstructured":"Pittock SJ et al (2022) Eculizumab monotherapy for NMOSD: data from PREVENT and its open-label extension. Mult Scler 28(3):480\u2013486. https:\/\/doi.org\/10.1177\/13524585211038291","journal-title":"Mult Scler"},{"issue":"6","key":"13647_CR28","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/ana.26626","volume":"93","author":"SJ Pittock","year":"2023","unstructured":"Pittock SJ et al (2023) Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Ann Neurol 93(6):1053\u20131068. https:\/\/doi.org\/10.1002\/ana.26626","journal-title":"Ann Neurol"},{"issue":"5","key":"13647_CR29","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/wnl.53.5.1107","volume":"53","author":"DM Wingerchuk","year":"1999","unstructured":"Wingerchuk DM, Hogancamp WF, O\u2019Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic\u2019s syndrome). Neurology 53(5):1107\u20131114. https:\/\/doi.org\/10.1212\/wnl.53.5.1107","journal-title":"Neurology"},{"key":"13647_CR30","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000640","author":"T Akaishi","year":"2020","unstructured":"Akaishi T, Nakashima I, Takahashi T, Abe M, Ishii T, Aoki M (2020) Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000000640","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13647_CR31","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0001051692.87068.50","author":"E Khan","year":"2024","unstructured":"Khan E, Sriwastava S, Kagzi Y, Amatya S (2024) Disease characteristics of NMOSD and their Relationship with disease burden: observations from a large single-center cohort. Neurology. https:\/\/doi.org\/10.1212\/01.wnl.0001051692.87068.50","journal-title":"Neurology"},{"key":"13647_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.679881","volume":"12","author":"R Cortese","year":"2021","unstructured":"Cortese R, Giorgio A, Severa G, De Stefano N (2021) MRI prognostic factors in multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin oligodendrocyte antibody disease. Front Neurol 12:679881. https:\/\/doi.org\/10.3389\/fneur.2021.679881","journal-title":"Front Neurol"},{"issue":"10","key":"13647_CR33","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1136\/jnnp-2018-320249","volume":"90","author":"A Papadopoulou","year":"2019","unstructured":"Papadopoulou A et al (2019) Attack-related damage of thalamic nuclei in neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry 90(10):1156\u20131164. https:\/\/doi.org\/10.1136\/jnnp-2018-320249","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"13647_CR34","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209940","volume":"103","author":"P Siriratnam","year":"2024","unstructured":"Siriratnam P et al (2024) Prevalence of progression independent of relapse activity and relapse-associated worsening in patients with AQP4-IgG-positive NMOSD. Neurology 103(12):e209940. https:\/\/doi.org\/10.1212\/WNL.0000000000209940","journal-title":"Neurology"},{"key":"13647_CR35","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000978","author":"R Marignier","year":"2021","unstructured":"Marignier R et al (2021) Disability outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000000978","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"13647_CR36","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210137","volume":"104","author":"B Chen","year":"2025","unstructured":"Chen B et al (2025) Quantitative contribution of clinical attacks to residual disability in patients with AQP4-antibody neuromyelitis optica spectrum disorder. Neurology 104(1):e210137. https:\/\/doi.org\/10.1212\/WNL.0000000000210137","journal-title":"Neurology"},{"key":"13647_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1099376","volume":"14","author":"A Berthele","year":"2023","unstructured":"Berthele A et al (2023) A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder. Front Neurol 14:1099376. https:\/\/doi.org\/10.3389\/fneur.2023.1099376","journal-title":"Front Neurol"},{"issue":"1 Spinal Cord D","key":"13647_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1212\/01.CON.0000461082.25876.4a","volume":"21","author":"TA Cho","year":"2015","unstructured":"Cho TA (2015) Spinal cord functional anatomy. Continuum 21(1 Spinal Cord Disorders):13\u201335. https:\/\/doi.org\/10.1212\/01.CON.0000461082.25876.4a","journal-title":"Continuum"},{"issue":"1","key":"13647_CR39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/ene.14038","volume":"27","author":"Y Nakamura","year":"2020","unstructured":"Nakamura Y et al (2020) Spinal cord involvement by atrophy and associations with disability are different between multiple sclerosis and neuromyelitis optica spectrum disorder. Eur J Neurol 27(1):92\u201399. https:\/\/doi.org\/10.1111\/ene.14038","journal-title":"Eur J Neurol"},{"issue":"7","key":"13647_CR40","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/ene.13011","volume":"23","author":"SH Kim","year":"2016","unstructured":"Kim SH et al (2016) Widespread cortical thinning in patients with neuromyelitis optica spectrum disorder. Eur J Neurol 23(7):1165\u201373. https:\/\/doi.org\/10.1111\/ene.13011","journal-title":"Eur J Neurol"},{"issue":"7","key":"13647_CR41","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1136\/jnnp-2020-324826","volume":"92","author":"Y Duan","year":"2021","unstructured":"Duan Y et al (2021) Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS. J Neurol Neurosurg Psychiatry 92(7):709\u2013716. https:\/\/doi.org\/10.1136\/jnnp-2020-324826","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"13647_CR42","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/jnnp-2021-326386","volume":"93","author":"H Masuda","year":"2022","unstructured":"Masuda H et al (2022) Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. J Neurol Neurosurg Psychiatry 93(1):32\u201340. https:\/\/doi.org\/10.1136\/jnnp-2021-326386","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"13647_CR43","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/ana.26951","volume":"96","author":"R Cortese","year":"2024","unstructured":"Cortese R et al (2024) Grey matter atrophy and its relationship with white matter lesions in patients with myelin oligodendrocyte glycoprotein antibody-associated disease, aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder, and multiple sclerosis. Ann Neurol 96(2):276\u2013288. https:\/\/doi.org\/10.1002\/ana.26951","journal-title":"Ann Neurol"},{"issue":"2","key":"13647_CR44","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/jnnp-2016-313300","volume":"88","author":"I Kawachi","year":"2017","unstructured":"Kawachi I, Lassmann H (2017) Neurodegeneration in multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry 88(2):137\u2013145. https:\/\/doi.org\/10.1136\/jnnp-2016-313300","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"13647_CR45","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1007\/s13311-020-00973-9","volume":"18","author":"Y Xu","year":"2021","unstructured":"Xu Y et al (2021) Persistently gadolinium-enhancing lesion is a predictor of poor prognosis in NMOSD attack: a clinical trial. Neurotherapeutics 18(2):868\u2013877. https:\/\/doi.org\/10.1007\/s13311-020-00973-9","journal-title":"Neurotherapeutics"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13647-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13647-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13647-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T22:04:11Z","timestamp":1773785051000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13647-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["13647"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13647-x","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M. Margoni reports grants and personal fees from Sanofi Genzyme, Merck Serono, Roche, Biogen, Amgen and Novartis. M. Gueye, A. Meani, E. Pagani, P. Valsasina L. Storelli have nothing to disclose. P. Preziosa eceived speaker honoraria from Roche, Biogen, Novartis, Merck, Bristol Myers Squibb, Genzyme, Horizon and Sanofi, he has received research support from Italian Ministry of Health and Fondazione Italiana Sclerosi Multipla. L. Moiola received compensation for speaking activities, travel grant, and participation in advisory board from Biogen, Bristol-Myers Squibb, Novartis, Roche, Sanofi-Genzyme, Merck-Serono, Biogen, and Alexion. M.A. Rocca received consulting fees from Biogen, Bristol Myers Squibb, Roche; and speaker honoraria from Alexion, Biogen, Bristol Myers Squibb, Celgene, Horizon Therapeutics Italy, Merck Serono SpA, Mitsubishi-Tanabe Pharma, Neuraxpharm, Novartis, Roche, Sandoz, and Sanofi. She receives research support from the MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla. She is Associate Editor for\n                      Multiple Sclerosis and Related Disorders\n                      ; and Associate Co-Editor for Europe and Africa for\n                      Multiple Sclerosis Journal\n                      . M. Filippi is Editor-in-Chief of the\n                      Journal of Neurology\n                      , Associate Editor of\n                      Human Brain Mapping\n                      ,\n                      Neurological Sciences,\n                      and\n                      Radiology\n                      , received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi, speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA, participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda, scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, Sanofi-Genzyme, he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"Approval was received from the institutional ethical standards committee (Protocol 46\/INT\/2020) on human experimentation of IRCCS Ospedale San Raffaele for any experiments using human subjects. Written informed consent was obtained from all subjects prior to study participation according to the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"112"}}